Stockscreener 앱 받기
1.06
0.00%
0.00
시장 영업 전:
1.14
0.08
+7.55%
전일 마감가:
$1.06
열려 있는:
$1.08
하루 거래량:
354.42K
Relative Volume:
0.54
시가총액:
$122.19M
수익:
-
순이익/손실:
$-26.33M
주가수익비율:
-3.7535
EPS:
-0.2824
순현금흐름:
$-17.65M
1주 성능:
+0.95%
1개월 성능:
-19.70%
6개월 성능:
+6.00%
1년 성능:
-22.63%
1일 변동 폭
$1.05
$1.10
1주일 범위
$1.02
$1.10
52주 변동 폭
$0.88
$1.71
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
명칭
Cardiol Therapeutics Inc
전화
-
주소
-
Compare CRDL vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.06 | 121.04M | 0 | -26.33M | -17.65M | -0.2824 |
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.87 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.56 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.26 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
551.47 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-02 | 개시 | H.C. Wainwright | Buy |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-26 | 개시 | ROTH MKM | Buy |
| 2024-04-22 | 개시 | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc 주식(CRDL)의 최신 뉴스
Why Cardiol Therapeutics Inc Class A stock is sliding today - Wealth Awesome
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Moderna to Present at Upcoming Conference in June 2026 - Investing News Network
CRDL Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost DisciplineConsensus Miss Rate - newsline.com
Cardiol Therapeutics (CRDL) Dips 4.7% as Shares Test Key Support LevelsWave Truncation - The Legal Advocate
Cardiol Therapeutics Sets June 24, 2026 Virtual AGM and Adopts Notice-and-Access for Proxy Materials - TipRanks
Cardiol Therapeutics (Nasdaq: CRDL) outlines 2026 virtual shareholder meeting - Stock Titan
Cardiol Therapeutics Inc. (CRDL) Modestly Advances as It Holds Above Key SupportStop Hunt - The Legal Advocate
Cardiol Therapeutics Inc CRDL Modestly Advances as It Holds Above Key SupportThe Legal Advocate - The Legal Advocate
CRDL Q4 2025 Earnings: Narrower Loss Surpasses Estimates Amid Clinical ProgressSurprise Factor Analysis - newsline.com
CRDL Q4 2025 Earnings: Loss Narrows as EPS Beats Estimates by 14.2%Financial Data - newsline.com
CRDL Q4 2025 Earnings: Narrower Than Expected Loss as Cardiol Therapeutics Advances Clinical PipelineEPS Revision Trend - newsline.com
CRDL Stock Chart | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL) - ChartMill
Cardiol Therapeutics Inc (TSX:CRDL) Stock Price & 30 Year Financial Data - GuruFocus
CCORF Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $8 - Moomoo
CRDL News | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL) - ChartMill
(CRDL) On The My Stocks Page (CRDL:CA) - Stock Traders Daily
[SCHEDULE 13G/A] Cardiol Therapeutics Inc. Amended Passive Investment Disclosure - Stock Titan
Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation - Yahoo Finance
Cardiol Therapeutics Inc.Class A Common Shares (NQ: CRDL - FinancialContent
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
TradingKey - TradingKey
Cardiol Therapeutics to Present Pipeline at H.C. Wainwright BioConnect Conference at NASDAQ - TipRanks
Cardiol Therapeutics (CRDL) joins H.C. Wainwright BioConnect investor Fireside Chat at NASDAQ - Stock Titan
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ - The Globe and Mail
Heart disease life sciences firm Cardiol joins Nasdaq investor chat - Stock Titan
H.C. Wainwright Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Cardiol Therapeutics Reports Higher Q1 2026 Loss but Stronger Cash Position - TipRanks
Cardiol Therapeutics (CRDL) extends cash runway and advances late-stage heart trials - Stock Titan
Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cardiol Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Cardiol Therapeutics’ Phase II MAvERIC Pericarditis Data Accepted by JAHA as Phase III Trial Nears Completion - TipRanks
Phase II MAvERIC data for CardiolRx in pericarditis to appear in JAHA for Cardiol (NASDAQ: CRDL) - Stock Titan
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association - PR Newswire
Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
CRDL Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL) - ChartMill
CRDL.CA Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (TSX:CRDL) - ChartMill
Phase III Trial Enrollment Reached (75%) for Promising Anti-Inflammatory and Anti-Fibrotic Cardiac Therapies by Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) - Barchart.com
Phase III Trial Enrollment Reached (75%) for Promising - openPR.com
User - The Chronicle-Journal
Ellis Martin Report: Cardiol Therapeutics (TSE.CRDL) CEO David Elsley on Breakthrough Heart Disease Treatment - ABN Newswire
Cardiol Therapeutics (CRDL) Expands MAVERIC Trial with New Clini - GuruFocus
Cardiol Therapeutics expands Phase III trial to 25 sites By Investing.com - Investing.com India
Cardiol Therapeutics expands Phase III trial to 25 sites - Investing.com UK
Cardiol Therapeutics Expands U.S. Phase III MAVERIC Trial Network as Enrollment Reaches 75% - TipRanks
Cardiol Therapeutics (NASDAQ: CRDL) expands U.S. MAVERIC Phase III trial network - Stock Titan
Cardiol Therapeutics Inc. Expands Maveric Phase III Trial Network and Provides Clinical Updates on Cardiolrx - marketscreener.com
Correction: Positive Results on MAVERIC Phase 2 and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL) - Barchart.com
Correction: Positive Results on MAVERIC Phase 2 and Published - openPR.com
Cardiol Therapeutics Inc (CRDL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.95%
1.13%
자본화:
|
볼륨(24시간):